The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by
The Food and Drug Administration has cleared a nonuniform attenuation correction package developed by nuclear medicine firm ELGEMS of Tirat Hacarmel, Israel. The upgrade, called VTransACT, works on dual-head variable-angle gamma cameras manufactured by ELGEMS, which are sold by Elscint as VariCam and by GE Medical Systems as Millennium VG. Elscint plans to begin shipments of VTransACT for VariCam in the first quarter of 1999, according to a spokesperson for the company. ELGEMS also received 510(k) clearance for a set of ultra-high-energy collimators, called VPC-94. The collimators are designed to be used on VariCam for FDG cardiac imaging.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.